Efficacy of Nutritional Supplementation on Physical-activity Mediated Changes in Physical Functioning Older Adults at Risk for Mobility Disability (The VIVE2 Study)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01542892 |
Recruitment Status :
Completed
First Posted : March 2, 2012
Last Update Posted : November 18, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sarcopenia | Other: Exercise Intervention Dietary Supplement: Supplement Intervention | Not Applicable |
Exercise Intervention: Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
Supplement Intervention: Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
Primary Outcome: The primary outcome will be the time to walk 400 meters, expressed as average gait speed during the 400 M walk. All participants must be able to walk 400 meters in <15 minutes at walking at their normal speed. The 400 M walk will be assessed at baseline, 3-months, and 6-months, with the changes at 6-months being the primary outcome.
Secondary Outcome Measures:
- Stair Climb Test
- Body Composition
- Skeletal muscle cross sectional area
- Isokinetic/Isometric peak torque/power
- Hand-grip strength
- Nutritional status
- Quality of Life/Depressive symptoms Expected enrollment: 150 (80 at Tufts University (Boston, MA, USA), 70 at University of Uppsala (Uppsala, Sweden))
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 150 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Efficacy of Nutritional Supplementation on Physical-activity Mediated Changes in Physical Functioning Older Adults at Risk for Mobility Disability (The VIVE2 Study) |
Study Start Date : | October 2011 |
Actual Primary Completion Date : | August 2014 |
Actual Study Completion Date : | August 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Supplement |
Dietary Supplement: Supplement Intervention
Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session. |
Sham Comparator: Placebo |
Dietary Supplement: Supplement Intervention
Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session. |
Experimental: Exercise |
Other: Exercise Intervention
Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training. |
- Time to Walk 400 meters [ Time Frame: 6-Month ]The primary outcome will be the time to walk 400 meters, expressed as average gait speed during the 400 M walk. All participants must be able to walk 400 meters in <15 minutes at walking at their normal speed. The 400 M walk will be assessed at baseline, 3-months, and 6-months, with the changes at 6-months being the primary outcome.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 70 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male & Female ≥ 70 yrs
- Community dwelling
- Short Physical Performance Battery ≤ 9
- Willingness to be randomized and come to the laboratory for 6 months
- Body Mass Index < 35
- Mini-Mental State Examination >=24
- Serum 25 (OH) D (22.5 -50 nmol/l)
- Having obtained his/her informed consent
- Able to complete 400 M walk within 15 minutes
Exclusion Criteria:
-
• Acute or terminal illness; terminal illness with life expectancy less than 12 months, as determined by a physician
- Current regular use (> 1 per week) of high protein oral nutritional supplements (eg: Boost, Exceed etc…)
- Current use of Vitamin D supplements, >800 IU/day
- Myocardial infarction in previous 6 months, symptomatic coronary artery disease, or congestive heart failure.
- Upper or lower extremity fracture in previous 6 months.
- Hemoglobin < 10 g/dL, Estimated GFR < 30 mL/min/1.73 m2
- Uncontrolled hypertension (>150/90 mm Hg).
- Neuromuscular diseases and drugs which affect neuromuscular function; severe progressive, degenerative neurologic disease
- Hormone replacement therapy
- Insulin-dependent diabetes mellitus
- Milk protein allergy
- Major surgery in the past 6 months (requiring general anesthesia)
- Other significant co-morbid disease that would impair ability to participate in the exercise-based intervention, e.g. renal failure on hemodialysis, severe psychiatric disorder (e.g. bipolar, schizophrenia)
- Excessive alcohol use (>14 drinks per wk)
- Participation in moderate intensity physical activity > 20 minutes/week
- Inability to communicate due to severe, uncorrectable hearing loss or speech disorder
- Severe visual impairment (if it precludes completion of assessments and/or intervention)
- Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement, active inflammatory disease; wheelchair bound
- Cancer requiring treatment in the past three years, except for non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer)
- Severe pulmonary disease, requiring either steroid pills or injections or the use of supplemental oxygen
- Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina
- Patient who cannot be expected to comply with treatment, as decided by the Principal Investigator and study physician.
- Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the clinical site Principal Investigator and/or study physician.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01542892
United States, Massachusetts | |
Jean Mayer Human Nutrition Research Center on Aging at Tufts University | |
Boston, Massachusetts, United States, 02111 | |
Sweden | |
Uppsala University | |
Uppsala, Sweden, 75185 |
Principal Investigator: | Roger Fielding, PhD | Tufts University |
Responsible Party: | Tufts University |
ClinicalTrials.gov Identifier: | NCT01542892 |
Other Study ID Numbers: |
10.27.CLI |
First Posted: | March 2, 2012 Key Record Dates |
Last Update Posted: | November 18, 2014 |
Last Verified: | November 2014 |
Sarcopenia Nutrition Vitamin D Exercise |
Sarcopenia Muscular Atrophy Neuromuscular Manifestations Neurologic Manifestations |
Nervous System Diseases Atrophy Pathological Conditions, Anatomical |